Clinical Lab Results Data Helps Pharma Assess COVID-19 Impact

Clinical Lab Results Data Helps Pharma Assess COVID-19 Impact

Did you know that 70% of medical diagnosis are informed by clinical lab results data?


Over the past five months, round-the-clock news reports have kept us well informed of data related to patients testing positive for COVID-19. People everywhere have been closely following this data in an attempt to gauge – and hopefully control – the impact of the virus.


Critical insights about the patient journey can, however, also be gained by analyzing the lab results of people testing negative for COVID-19, as well as those who have developed the antibodies for the virus – patients who have recovered from COVID-19 or a-symptomatic patients who may or may not have been tested previously.


Armed with clinical lab results information, pharma has a strategic advantage in developing clinical trials and real-world retrospective cross-over studies to assess the impact of COVID-19 on patients with chronic conditions, such as Diabetes and Cardiovascular and Kidney diseases.


For pharma companies with in-line therapies for chronic conditions, lab (and other data) is readily available to assess the potential disruption of the efficacy of existing therapies – for patients with COVID-19.


MSA’s healthcare data management solutions provide the tools pharma needs to accurately analyze the journey of patients with chronic diseases by linking clinical lab results, prescriptions, EMR and medical claims data – all while protecting patient privacy – enabling pharma to

  • Drive innovative research
  • Improve patient outcomes
  • Assess performance of in-line brands
  • Reduce healthcare costs


MSA provides the Life Sciences industry the most credentialed, configurable, and trusted de-identification and data management services and solutions. Contact the HCDM Team for more information about MSA Healthcare Data Management solutions.

Marianne Ryan
No Comments

Sorry, the comment form is closed at this time.